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AbstractWord count 273
The prevalence of concurrent HBsAg and anti-HBs in plasma of persons with chronic hepatitis B 
virus (HBV) infection is variable and its clinical significance enigmatic. We examined the 
prevalence,clinical and virological features of concurrent HBsAg and anti-HBs inchildren and 
adults with chronic HBV infection living in North America. A total of 1,462 HBsAg positive 
participants in the Hepatitis B Research Network pediatric and adult cohorts were 
included[median age 41 (range 4-80) years, 48% female, 11% white, 13% black, 73% Asians]. 
Only 18 (1.2%) were found to be anti-HBs positive (≥10 mIU/mL) at initial study 
evaluation.Distributions of sex, race, HBV genotype, and ALTwere similar between participants 
with and without concurrent anti-HBs. Those who were anti-HBs positive appeared to be older 
(median age 50 vs. 41 years,p=0.06), hadlower platelet counts (median 197 vs. 222 x 103/mm3, 
p=0.07)and higher prevalence of HBeAg (44% vs. 26%, p=0.10). They also had lower HBsAg 
levels (median 2.0 vs. 3.5 log10 IU/mL, p=0.02).Testing of follow-up samples after a median of 4 
years (range 1-6)in 12 of the 18 participants with initial concurrent anti-HBsshowed anti-HBs 
became undetectable in 6, decreased to <10 mIU/mL in 1and remained positive in 5 
participants.Two patients lost HBsAg during follow-up. In conclusion, prevalenceof concurrent 
HBsAg and anti-HBs was low at 1.2%,with anti-HBs disappearing in some during follow-up, in 
this large cohort of racially diverse children and adults with chronic HBV infection living in North 
America. Presence of concurrent HBsAg and anti-HBs did not identify a specific phenotype of 
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Introduction
The simultaneous presence in plasma of hepatitis B surface antigen (HBsAg) and 
antibody (anti-HBs) in patients with chronic hepatitis B virus (HBV) infection has long puzzled 
clinicians and investigators. The presence of both antigen and antibody typically results in 
immune complex formation and removal from the circulation(1).First reported in the 1970s, the 
most frequent explanation offered is that anti-HBs in this setting represents heterotypic 
antibodies not directed against the common ‘a’ determinant or the circulating HBV serotype(2-
10). Alternatively, anti-HBs may not be neutralizing because of expression of variant HBsAg not 
recognized by anti-HBs (immune escape variant resulting from mutations in the S gene) (11-20).
Reported prevalence of concurrent HBsAg and anti-HBs has varied greatly, from 5-60%. 
Early United States (US) studies found concurrent HBsAg and anti-HBs present in 24% (64/269) 
and 32% (61/190) of patients, respectively(6,8), with a higher prevalence in patients with active 
hepatitis and hepatitis B e antigen (HBeAg)positivity (8). Larger recent studies have found lower 
(<10%) prevalence of concurrent HBsAg and anti-HBs(13-16, 19-23). In summary, existing 
literature indicatesa wide range in prevalence of concurrent HBsAg and anti-HBs in patients 
with chronic HBV infection and conflicting associations with activity of HBV replication and liver 
disease (6-23). Many of the early studies were limited by small numbers and possible selection 
bias, with little data on persistence of anti-HBs or HBsAg clearance. We sought to evaluate the 
prevalence, and clinical and virologic attributes of concurrent HBsAg and anti-HBs in a large 
sample of patients with chronic HBV infection participating in the Hepatitis B Research Network 
(HBRN) pediatric and adult cohortstudies. A secondary aim was to evaluate the stability of 
concurrent HBsAg and anti-HBs over time.
Methods
Study design
The HBRN is a clinical research network, funded by the National Institute for Diabetes 
and Digestive and Kidney Diseases at the National Institutes of Health, that enrolled patients 
with HBV infection into pediatric and adult cohortstudies from 2012-2017.Details of the HBRN 
cohort study protocols have been previously described (24,25). All 21 adult and 7 pediatric sites 
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no history of hepatic decompensation, hepatocellular carcinoma, liver transplant, or known HIV 
infection. 
Participant evaluations included a medical history, a brief physical examination, 
completion of questionnaires,standard of care tests, and collection of blood samples for 
research-related testing.In addition, relevant clinical, laboratory, radiological, and histological 
data werecollected from participants’ medical records.After enrollment, adult participants were 
seen at week 12, 24 and then every 24 weeks (i.e., bi-annually); and pediatric participants at 
week 24, 48 and then every 48 weeks (i.e., annually). 
The protocols governing this research were approved by the institutional review boards 
of each participating institution and each participant gave written, informed consent for his/her 
participation.In the case of minors, written informed consent was given by their parent or 
guardian and, where possible, the children themselves gave assent to participate.All authors 
had access to the study data and reviewed and approved the final manuscript.
Central HBV testing
Qualitative and quantitative HBsAg, quantitative HBeAg, and quantitative HBV DNA 
testing were performed on samples from annual assessments at the University of 
Washington.Quantitative HBeAg and HBV DNA were also tested with samples from bi-annual 
assessments among adults.HBV DNA levels were determined using a real-time PCR assay 
(COBAS Ampliprep/COBAS TaqMan HBV Test, v2.0; Roche Molecular Diagnostics, Branchburg, 
NJ) with a lower limit of detection (LLOD) of 10 IU/mL and a lower limit of quantification (LLOQ) 
of 20 IU/mL.Quantitative HBeAg and HBsAg were tested using the Roche Diagnostics Elecsys 
platform with LLOD and LLOQ of 0.3 IU/mL for HBeAg and 0.05 IU/mL for HBsAg.HBsAg and 
HBV DNA were log transformed (log10) for analysis. HBV genotype was determinedusing 
automated mass spectrometry at the Molecular Epidemiology and Bioinformatics Laboratory in 
the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (26).
Baseline determination of quantitative anti-HBs testing was added to the HBRN cohort 
study protocols in 2018 because anti-HBs testing had not been consistently done at local 
sites.Quantitative anti-HBs testing was performed at the University of Texas Southwestern 
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LLOQ was 5 mIU/mL and ≥10 mIU/mL was considered positive (18). The first available sample of 
HBRN participants with chronic HBV infection,and no co-infection (HCV, HDV or HIV), collected 
up to 2 yearspast enrollment was used to determine baseline prevalence of concurrent HBsAg 
and anti-HBs, defined as positive HBsAg and anti-HBs ≥10 mIU/mL.Samples collected while 
participants were on HBV treatment or pregnant were excluded. Among those who were anti-
HBs positive at baseline, blood samples collected from an assessment at least one yearafter the 
first sample and at participants’ last assessment (if at least 3 years from the first sample and at 
least1 year from the second sample) were also tested for quantitative anti-HBs regardless of 
treatment status to determine persistence of anti-HBs.
Statistical analyses
Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). 
Reported p-values are two-sidedand were used to guide interpretation of results (27). The Chi-
Square test, Fisher-exact test and the Wilcoxon-Rank Sum test, as appropriate, were used to 
test for associations between demographic, clinical and virological features and concurrent 
HBsAg and anti-HBs.Box plots were used to visualize the distribution of quantitative HBsAg and 
HBV DNA levels in participants with and without concurrent anti-HBs. Scatter plots were used 
to visualize the distribution of anti-HBs levels in relation to quantitative HBsAg and HBV DNA 
levels, and Pearson correlation coefficients are reported.
Results
A total of 2,340adult and pediatric participants with chronic HBVinfection and no HCC or 
HIV co-infection had enrolled in the HBRN study at the time samples for this ancillary study 
were selected.Of these,971 participants were excluded due toinsufficientstored research blood 
sampleswithin 2 years of enrollment. The remaining1462 participants were included in this 
analysis. Of these, anti-HBs testing was performed using serum drawn at enrollment in 1263 
(86.4%) participants and between enrollment and year 2 in the remaining participants.
Of the 1,462 (124 children and 1,338 adults) participants tested for anti-HBs, 18 (1.2%) 
tested positive [1/123 (0.8%) children and 17/1321 (1.3%) adults]. An additional 13 (0.9%) 
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anti-HBs negative. Table 1 compares the demographics, clinical and virologic features of the 
participants with and without concurrent anti-HBs. The two groups had similar distributions of 
sex, race, and place of birth but the anti-HBs positive group appeared to be older (median age 
49.8 vs. 41.3 years; p=0.06).
Clinical and virologic features
The two groups were similar in prevalence of hepatitis C or D co-infections, distribution 
of HBV genotypes, family history of HBV infection, and prior HBV treatment, as well as  median 
serum aspartate and alanine aminotransferase (AST, ALT) levels(Table 1).HBsAg levels were 
lower in those with concurrent anti-HBs (median 2.0 vs. 3.5 log10 IU/mL, p=0.02;Figure S1A), 
along with somewhat higher serum HBV DNA levels (median 4.9 vs. 3.7 log10 IU/mL, 
p=0.20;Figure S1B),although one(5.6%) had undetectable serum HBV DNA (case 6; Table 2).ALT 
levels were not significantly different between groups (1.3 vs. 1.4, p=0.55; Figure S1C).
Anti-HBs levels were below 50 mIU/mL in nearly all(15 of 18)concurrent anti-HBs 
participants, the highest level being 95 mIU/mL. Among participants with concurrent anti-HBs, 
correlations between anti-HBs levels and HBsAg (r=0.35, p=0.16) and HBV DNA levels (r=0.41, 
p=0.09) were weak (Figure S2A and 2B). 
Persistence of anti-HBs
Among the 18 participants with concurrent anti-HBs at baseline, 12 had stored samples 
for one follow-up and 10 for two follow-uptests. Of these 12,anti-HBs levels remained ≥10 
mIU/mL in 5 participants(cases 1-5), decreased to <10 mIU/mL but remained detectable in 1 
participant (case 6), and became undetectable in 6 participants(cases 7-12), (Table 2).Three of 6 
in whom anti-HBs became undetectable had started HBV treatment first (case 7, 10, 12).
Figures with viral markers across time for the 12 participants with follow-up anti-HBs 
data are provided in supplemental material (Figure S3). In general, HBsAg levels were largely 
unchangedduring follow-up.All 6 participants with decreases in HBV DNA were on HBV 
treatment (Table 2 and Figure S3). 
Outcomes:HBsAg loss, hepatic decompensation and hepatocellular carcinoma
During a median follow-up of 5.5 years (range 1.2-6.4), 2 of the 12 participants with 
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6). One participant (case 6) first became HBsAg negative 3.5 years after baseline. The other 
participant (case 3) first became HBsAg negative 4.1 years after baseline but HBsAg was 
transiently positive again at low level (2 IU/mL) at 4.9 years when anti-HBs was positive at 41.3 
mIU/mL(Table 2). 
None of the 14participants with concurrent anti-HBs at baseline who returned for 
follow-up developed hepatic decompensation or hepatocellular carcinoma.
Discussion
This large study provided a unique opportunity to assess prevalence and durability of 
concurrent HBsAg and anti-HBs among persons with chronic HBV infection in North America. 
The very low overall prevalence of 1.2%, 0.8% in children and 1.3% in adults, islower than the 
two US adult studies from the 1980s(6,8). Reasons for these differences include ourexclusion of 
thosereceiving antiviral therapy at enrollment; as a result, most participants had low level HBV 
replication and inactive liver disease. Notably, we did not observe differences in AST, ALT or 
HBV DNA levels between participants with and without concurrent anti-HBs. Second, exclusion 
of patients on treatment also virtually eliminated patients with cirrhosis, whomight be more 
likely to have concurrent anti-HBs.Third, we used anti-HBs level ≥10 mIU/mL to define positive 
anti-HBs, whereas the previous US studies used any detectable level anti-HBs. However, even if 
we had included the 13 participants with detectable anti-HBs (i.e.,≥5mIU/mL) but levels <10 
mIU/mL, the prevalence of concurrent anti-HBs would only be 2.1%.
Our study’s low prevalence of concurrent HBsAg and anti-HBs is consistent withseveral 
more recent large studies including ≥1,000 participants each:using anti-HBs ≥10 mIU/mL as 
cutoff; most of these studies showed a prevalence ≤5% (Table3). 
We did not find an association of concurrent HBsAg and anti-HBs with sex, race, country 
of birth, HBV genotype or ALT level, a finding similar to the majority of studies published since 
1980 (Table 3).Of thosestudies that examined associations with demographics, none reported 
an association with age or sex (10, 15, 16, 19, 20, 27, 28). While several previous studies, like 
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positivity (8, 28, 17),more did not (9, 10,14,15, 18, 19, 20, 21, 27).Likewise, most prior studies, 
like ours, reported no association with ALT (10, 14, 5, 16, 17, 19, 20, 27, 28). 
While prior studies suggested no specific pattern of HBsAg levels(10,14,16,18,19), we 
found a marked difference in HBsAg levels between participants with and without concomitant 
anti-HBs (median 2.0 vs. 3.5 log10 IU/mL). We hypothesize that the presence of anti-HBs may 
partially neutralize or bind to circulating HBsAg accounting for the lower HBsAg levels. In 
general, anti-HBs levels were quite low (range 10-95 mIU/mL), with a wide range in HBsAg 
levels (8-27,090 IU/mL) at baseline in the 18 participants with concurrent anti-HBs. Although 
there was no overall correlation between anti-HBs and HBsAg or HBV DNA, when the groups 
were separated into HBeAg positive and negative, a moderate correlation for the HBeAg 
positive subjects was apparent between anti-HBs and both HBsAg and HBV DNA titers (sFigure 
2).In summary, our data are in line with most published studies, showing lower anti-HBs levels 
in patients with concurrent HBsAg and anti-HBs, and no consistent association of HBV DNA 
levels to presence of concurrent HBsAg and anti-HBs(Table S1). 
Our study included children,diverse races and HBV genotypes, as well as provideddata 
on durability of concurrent anti-HBs,using a central lab for the anti-HBs measurements. 
However, the small number of participants with concurrent HBsAg and anti-HBs limited our 
statistical power for all analyses and our ability to examine the clinical significance of 
concurrent HBsAg and anti-HBs. Further limitations include the lack of HBV sequencing and 
HBsAg and anti-HBs serotyping data in the 18 participants with concurrent HBsAg and anti-HBs.  
In summary, we found a low prevalence of concurrent anti-HBs in this large cohort of 
racially diverse children and adults with chronic HBV infection living in North America. Our 
prevalence estimate contrasts with two much earlier US studies but resembles contemporary 
studies from Asia and Europe. There being no association with HBV replication or liver disease 
or signs of immune complex disease, there appear to be no important clinical implications to 
anti-HBs positivity in patients with chronic HBV infection. Anti-HBs levels were uniformly low 
and became undetectable in half during a median follow-up of 4 years.Concurrent HBsAg and 
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resolution; thus, patients with chronic HBV infection who are anti-HBs positive should be 
managed similarly to those who are anti-HBs negative. 
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Supplementary Figure Legends
SupplementaryFigure 1. Box plot showing HBsAg level (A), HBV DNA level (B), and ALT level (C) 
among children and adults with chronic HBV infection by anti-HBs status.
SupplementaryFigure 2. Scatter plots of anti-HBs level by HBsAg level (A) and HBV DNA level (B) 
at baseline in children and adults with chronic HBV with concurrent HBsAg and anti-HBs.  
HBeAg status indicated.
Abbrevi ; anti-H  he surface antibody
There were significant positive correlations between anti-HBs levels and HBsAg and DNA 
(r=0.73, p=0.04; r=0.74, p=0.03, respectively), among HBeAg positive participants only. 
SupplementaryFigure 3. Anti-HBs, HBsAg, HBV DNA and levels over time in participants with 
chronic HBV infection and concurrent anti-HBs and HBsAg at baseline.  No participants were 
receiving HBV treatment (Rx) at baseline. Among participants who initiated treatment during 


















Table 1. Demographics, clinical and virologic characteristics among HBsAg positive children and adults with chronic HBV 










Age, years                              0.06 
     Median(25th, 75th)                                         41.3 (31.3, 52.0) 41.3 (31.3, 51.9) 49.8 (36.3, 63.7)  
     Min, Max                                                   4.0, 80.2 4.0, 80.2 16.1, 75.3  
Age, years    0.23 
    <18  124 (8.5) 123 (99.2) 1 (0.8)  
    18-<30 203 (13.9) 201 (99.0) 2 (1.0)  
    30-<40 345 (23.6) 341 (98.8) 4 (1.2)  
    40-<50 355 (24.3) 353 (99.4) 2 (0.6)  
    ≥50 435 (29.8) 426 (97.9) 9 (2.1)  
Gender, n (%)                                                          0.51 
    Male                                                      763 (52.2%) 755 (99.0%) 8 (1.0%)  
    Female                                                    699 (47.8%) 689 (98.6%) 10 (1.4%)  
Race, n (%)  n=1458 n=1440  0.95 
    White                                                     164 (11.2%) 163 (99.4%) 1 (0.6%)  
    Black                                                     189 (13.0%) 187 (98.9%) 2 (1.1%)  
    Asian                                                     1066 (73.1%) 1051 (98.6%) 15 (1.4%)  
    Other                                                     39 (2.7%) 39 (100.0%) 0 (0.0%)  
Place of birth, n (%)                                              n=1460 n=1442  0.87 
    United States/Canada 269 (18.4%) 267 (99.3%) 2 (0.7%)  
    Other North America/South America 21 (1.4%) 21 (100.0%) 0 (0.0%)  
    Europe 53 (3.6%) 53 (100.0%) 0 (0.0%)  
    Asia/Australia 987 (67.6%) 972 (98.5%) 15 (1.5%)  
    Africa 130 (8.9%) 129 (99.2%) 1 (0.8%)  
HDV+    0.42 
    No 1419 (97.1%) 1402 (98.8%) 17 (1.2%)  
    Yes 43 (2.9%) 42 (97.7%) 1 (2.3%)  
HCV+    0.99 
     No 1437 (98.3%) 1419 (98.7%) 18 (1.3%)  
   Yes 25 (1.7%) 25 (100.0%) 0 (0.0%)  
Known family history of chronic HBV, n (%)         n=1137 n=1124 n=13 0.99 
    No 410 (36.1%) 405 (98.8%) 5 (1.2%)  



















Prior HBV treatment, n (%)    0.73 
    No 1256 (85.9%) 1241 (98.8%) 15 (1.2%)  
    Yes 206 (14.1%) 203 (98.5%) 3 (1.5%)  
HBeAg, n (%)  n=1459 n=1441  0.10 
    Negative 1074 (73.6%) 1064 (99.1%) 10 (0.9%)  
    Positive                                                  385 (26.4%) 377 (97.9%) 8 (2.1%)  
HBsAg (log10 IU/mL) n=1393 n=1376 n=17 0.02 
     Median(25th:75th)                                         3.5 (2.7: 4.2) 3.5 (2.7: 4.2) 2.0 (1.7: 4.2)  
HBV DNA (log10 IU/mL) n=1461 n=1443  0.20 
     Median(25th:75th)                                         3.7 (2.6: 6.0) 3.7 (2.6: 6.0) 4.9 (3.4: 5.8)  
Genotype, n (%)                                                    n=1359 n=1342 n=17 0.57 
     A-1                                                         92 (6.8%) 92 (100.0%) 0 (0.0%)  
     A-2 126 (9.3%) 125 (99.2%) 1 (0.8%)  
     B                                                         530 (39.0%) 522 (98.5%) 8 (1.5%)  
     C                                                         434 (31.9%) 427 (98.4%) 7 (1.6%)  
     D                                                         127 (9.3%) 127 (100.0%) 0 (0.0%)  
     E                                                         36 (2.6%) 35 (97.2%) 1 (2.8%)  
     Other                                                     14 (1.0%) 14 (100.0%) 0 (0.0%)  
ALT xULNc n=1426 n=1409 n=17 0.55 
     Median(25th:75th)                                         1.3 (0.9: 2.0) 1.3 (0.9: 2.0) 1.4 (1.0: 2.7)  
AST xULNd n=1404 n=1387 n=17 0.67 
     Median(25th:75th)                                         0.7 (0.6: 1.0) 0.7 (0.6: 1.0) 0.8 (0.6: 1.1)  
Platelets (x103/mm3) n=1264 n=1250 n=14 0.07 
     Median(25th:75th)                                         221 (183.5: 259) 221.5 (184: 259) 196.5 (167: 223)  
Abbreviations: ALT, Alanine aminotransferase; DNA, deoxyribonucleic acid; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface 
antigen; HCV, Hepatitis C virus; HDV, Hepatitis D virus, ULN, upper limit of the normal range. 
aAnti-HBs+ was defined as anti-HBs ≥10 mIU/mL. 
bData are reported among this sample unless a smaller number is indicated due to missing data. 
cThe ULN for ALT was standardized based on sex and age (i.e., ≤33 U/L for males and females ages < 1 year; ≤25 U/L for males and 
females ages 1 year-<13 years; ≤25 U/L for males and ≤22 U/L for females ages 13 years-<18 years; ≤30 U/L for adult males and ≤20 
U/L for adult females). 



















Table 2. Anti-HBs, HBsAg, qualitative HBeAg and HBV DNA levels over time in participants with chronic HBV infection 
















HBV DNA  
(log10 
IU/mL) 
ALT x ULN 
1 0.0 27 Inactive carrier 10.0 3.6 Negative 3.7 0.5 
 1.1 28 Inactive carrier . 3.6 Negative 3.6 0.6 
 1.9 29 Inactive carrier 12.6 3.5 Negative 3.5 0.5 
 2.9 30 Inactive carrier 10.0 3.5 Negative 3.5 0.6 
2 0.0 39 Inactive carrier 10.3 4.3 Negative 3.8 0.9 
 1.0 40 Indeterminate 29.1 4.3 Negative 3.7 2.1 
 2.3 42 Indeterminate . . Negative 3.6 1.2 
 2.9 42 Indeterminate 18.2 4.2 Negative 3.6 1.2 
 4.8 44 Indeterminate . 4.2 Negative 3.4 1.3 
3 0.0 69 HBeAg+ CHB 11.0 1.3 Positive 5.5 1.0 
 1.0 70 Unknown . 1.3 Positive 5.8 . 
 2.0 71 Immune 
tolerant 
15.0 1.4 Positive 5.4 0.9 
 2.7 72 Immune 
tolerant 
. 0.2 Positive 5.3 0.9 
 3.5 73 Immune 
tolerant 
. 1.0 Positive 5.2 1.2 
 4.9 74 Immune 
tolerant 
41.3 .02 Positive 5.2 0.9 
 5.6 75 HBsAg 
negative 
. Negativeb . 5.5 0.9 
 6.2 76 HBsAg 
negative 
. . Positive 5.1 1.1 
4 0.0 36 HBeAg+ CHB 112.9 4.5 Positive 8.1 3.0 
 0.9 37 HBeAg+ CHB 103.1 4.5 Positive 8.1 1.4 
 1.4 37 HBeAg+ CHB . . Positive 8.3 1.1 
5 0.0 33 HBeAg+ CHB 94.7 4.4 Positive 8.1 1.6 
 1.0 34 HBeAg+ CHB 156.6 4.5 Positive 8.1 3.0 
 6.4 39 HBsAg 
negative 
88.6 . . <LLOQc 0.6 
6 0.0 72 Indeterminate 13.1 Positiveb Negative <LLOD 1.4 
 1.0 73 Indeterminate 9.6 Positiveb Negative <LLOD 1.1 
 2.0 74 Indeterminate . Positiveb . . 1.2 
 3.0 75 Indeterminate . . . <LLOQ 1.3 
 4.5 76 HBsAg 
negative 
. Negativeb . <LLOQ 0.6 
 5.5 77 HBsAg 
negative 
. Negativeb . <LLOQ 0.9 
7 0.0 57 HBeAg+ CHB 15.9 1.8 Positive 5.8 2.5 
 0.8 57 HBV med . 1.5 Positive 2.2c 1.7 
 1.8 58 HBV med <LLOD 1.6 Negative <LLOD 0.9 
 2.7 59 HBV med <LLOD 1.6 Negative <LLOQ 0.8 
 3.7 60 HBV med . . . <LLOQ . 
 5.2 62 HBV med . . . <LLOQ . 
8 0.0 26 HBeAg+ CHB 40.6 4.3 Positive 8.3 3.0 
 0.9 27 HBeAg+ CHB . 4.3 Positive 8.2 2.2 



















 2.7 29 HBeAg+ CHB . 4.2 Positive 8.4 3.4 
 3.6 30 HBeAg+ CHB . 4.2 Positive 8.2 4.0 
 4.6 31 HBeAg+ CHB <LLOD 4.1 Positive 8.2 11.6 
 5.5 32 HBeAg+ CHB . Positiveb Positive 8.0 13.9 
9 0.0 60 Indeterminate 10.9 2.0 Negative 3.1 1.2 
 0.8 61 Indeterminate . 2.0 Negative 3.7 1.1 
 1.8 62 Inactive carrier . 1.9 Negative 1.6 0.9 
 2.8 63 Inactive carrier <LLOD 1.9 Negative 2.0 1.0 
 3.8 64 HBV med . 1.8 Negative <LLODc 1.6 
 4.6 65 HBV med . 1.7 Negative <LLOD 0.8 
 5.5 66 Inactive carrier <LLOD 1.5 Negative <LLOD 0.9 
 6.3 67 Inactive carrier . . . <LLOQ 0.9 
10 0.0 75 HBeAg- CHB 17.3 1.8 Negative 5.0 2.9 
 0.9 76 HBV med . 2.1 Negative <LLODc 0.8 
 1.8 77 HBV med <LLOD 2.2 Negative <LLOD 1.0 
 2.7 78 HBV med . 2.1 Negative <LLOD 1.1 
 3.6 78 HBV med . 2.1 Negative <LLOD 1.1 
 4.6 79 HBV med . 2.0 Negative <LLOD 1.2 
 5.5 80 HBV med <LLOD 2.0 Negative <LLOD 1.1 
 6.4 81 HBV med . Positiveb . <LLOQ 1.1 
11 0.0 49 Indeterminate 11.2 2.0 Negative 3.4 2.8 
 1.0 50 Indeterminate . 2.0 Negative 4.2 1.0 
 1.9 51 HBeAg- CHB 8.8 1.9 Negative 4.1 1.3 
 2.8 51 Indeterminate . 1.8 Negative 3.7 1.7 
 3.8 52 HBV med . 1.8 Negative <LLOQc 1.7 
 4.6 53 HBV med . . Negative <LLOQ 3.4 
 5.6 54 HBV med <LLOD 1.9 Negative <LLOQ 1.6 
 6.5 55 HBV med . . . <LLOQ 1.9 
12 0.0 63 Indeterminate 12.0 0.9 Positive 4.7 1.1 
 1.0 64 Indeterminate . 1.0 Positive 4.7 1.6 
 1.4 65 HBV med 9.9 . Positive 2.9c 1.2 
 1.8 65 HBV med . 1.5 Positive 1.4 1.2 
 2.8 66 HBV med . 2.2 Positive 1.5 1.2 
 3.6 67 HBV med <LLOD 2.7 Positive <LLOQ 1.0 
 4.6 68 HBV med . 3.0 Positive <LLOQ 0.9 
 5.5 69 HBV med . Positiveb Positive <LLOQ 1.0 
13d 0.0 67 HBeAg+ CHB 34.1 1.7 Positive 5.7 2.1 
 0.6 68 HBV med . . . 1.6c 1.1 
14d 0.0 45 HBeAg- CHB 27.1 2.7 Negative 5.6 2.7 
 5.3 50 HBV med . . . 3.1c 2.8 
15e 0.0 56 Indeterminate 40.9 1.4 Negative 2.2 1.2 
16e 0.3 36 Indeterminate 132.8 2.2 Negative 4.3 0.9 
17e 0.0 50 Inactive carrier 25.1 1.7 Negative 2.7 0.6 
18e 0.0 16 HBV med 23.8 4.2 Positive 7.2 . 
Abbreviations: ALT, alanine aminotransferase; DNA, deoxyribonucleic acid; HBsAg, hepatitis B surface antigen; LLOD = lower limit of 
detection, LLOQ = lower limit of quantification. 
LLOD and LLOQ were 5.0 mIU/mL for anti-HBs, 0.05 IU/mL for HBsAg, 10 and 20 IU/mL, respectively, for HBV DNA.  
aBaseline refers to time point when concurrent presence of HBsAg and anti-HBs was first determined; none of the participants were 



















bLocal laboratory results are reported when central laboratory testing was not performed. Only qualitative HBsAg testing was done at 
local laboratories. No participants were HBsAg negative by central laboratory qualitative testing.   
cStarted HBV treatment prior to this assessment. 
dCases 13-18 did not have stored samples available for follow-up anti-HBs testing.  
eCases 15-18 did not return for follow-up. 
fPhenotype was determined from HBeAg status, ALT and HBV DNA among HBsAg positive participants not taking HBV medication. 
Immune tolerant HBV infection was defined by the presence of normal serum ALT levels despite the presence of HBeAg and HBV DNA 
≥105 IU/mL. The diagnosis of “immune active” chronic hepatitis B was based on the presence of elevated ALT levels accompanied by 
high levels of HBV DNA (i.e., ≥105 IU/mL for HBeAg-positive and >104 IU/mL for HBeAg-negative patients). The inactive carrier state 
was defined by the presence of normal ALT levels and the absence of HBeAg with HBV DNA ≤104 IU/mL. Participants who did not fulfil 
criteria for one of these categories were categorized as having an “indeterminant” phenotype: HBeAg positive and low HBV DNA < 1 x 
105 IU/ml was indeterminate A, HBeAg negative, elevated ALT and HBV DNA ≤104 IU/mL was indeterminate B, and HBeAg negative, 




















Table 3. Prevalence of concurrent HBsAg and anti-HBs and associated factors in published studies of adults. 
 
Author/yr (ref) Country Anti-HBs 
cutoff, mIU/mL 
Anti-HBs+,             
n/N (%) 






Netherlands NR 32/89 (36.0) Advanced liver disease Risk factors for HBV  
Tsang/1986 (7) US NR 64/269 (23.9) NR NR 
Shiels/1987 (8) US NR 60/190 (31.6) HBeAg+,                         
active liver disease 
Risk factors for HBV, 
presence of HDV  
Hayashi/1990 
(9) 
Japan NR 166/638 (26.1)  None HBeAg, liver damage 
Wang/1996 
(21) 




None HBeAg, HBV DNA  
Lada/2006a (12) France NR 77/866 (8.9) NR NR 
Zhang/2007 
(10) 
China NR 20/411 (4.9) None Sex, age, ALT 
HBeAg, HBV DNA 
Colson/2007a 
(11) 
France  >10 13/459 (2.8) Lower HBV DNA level  
Jang/2009 (29) Korea >10, confirmed 
on repeat test 
after 6 months   
48/755 (6.4) HBeAg+, HCC Sex, age, ALT 
HBV DNA  
Huang/2010 
(13) 
China >10 34/1000 (3.4) None HBV DNA 
Chen/2011a 
(14) 
China  >10 72/1985 (3.6)  Lower HBsAg level,  
lower HBV DNA level 
HBeAg, ALT 
Liu/2012a (15) China  >10 54/1862 (2.9)  None Sex, age, ALT, HBeAg 
Lee/2013 (22) Korea >10 353/177,954 (2.9) Higher AST and ALT NA 
Seo/2014 (28) Korea NR 73/1042 (7.0) Higher incidence of 
HCC on follow-up 
Sex, age, ALT, 
cirrhosis, HBeAg, HBV 
DNA 
Ding/2015a (16) China  >10 39/1606 (9.8) None Sex, age, ALT, HBV 




France >10 129/2578 (5.0) NR NR 
Pu/2016 (17) China  NR 122/4169 (2.9) Older, HBeAg+,  
higher HBV DNA level 
Sex, ALT 



















lower HBsAg level,  
lower HBV DNA level 
Fu/2017a (19) China >10 145/5513 (2.6) Lower HBsAg level,  
Lower HBV DNA level  
Sex, age, ALT, HBeAg 
Xiang/2017 (30) China  NR 324/124,865 (0.3) NR NR 
Liu/2018a (20) China >10 179/4455 (4.0)  Sex, age, ALT, HBeAg, 
HBV DNA 
Current study US >10 18/1462 (1.2) Older age, lower 
platelets, HBeAg+, 
lower HBsAg level 
Sex, race, ALT, , HBV 
genotype, HBV DNA 
level, HCV or HDV 
infection 
Abbreviations: ALT, Alanine aminotransferase; DNA, deoxyribonucleic acid; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HCV, Hepatitis C 
virus; HDV, Hepatitis D virus; NR, not reported.  
aComparisons of persons with concurrent HBsAg and anti-HBs made with subset of controls.
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